Objective This study intends to introduce a model of cost-effective analysis by comparing olanzapine with haloperidol, which is the conventional treatment in refractory schizophrenia. Method Data from clinical trials were used to compare olanzapine with haloperidol in patients with refractory schizophrenia. Outcomes were compared among direct and indirect cost with the view point of health care provider at Ramathibodi Hospital and society in one year of treatment by path analysis and cost analysis, sensitivity analysis was shown for clinical decision when there is some cost or path probability have been changed so the decision will be changed at some threshold to another alternative. Results The total cost of olanzapine treatment to get one...
Australia and Canada are currently the only Western nations with government guidelines for analyzing...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
Objectives: To compare the annual costs of treating schizophrenia with four atypical antipsychotics-...
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight dr...
Background: Schizophrenia is a major public health problem throughout the world and known to be a ma...
OBJECTIVE: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
BACKGROUND: Many patients with schizophrenia exhibit only a partial response to conventional antipsy...
© 2019, Serbia Medical Society. All rights reserved. Introduction/Objective Although effectiveness o...
Background: Information on cost-effectiveness of interventions to treat schizophrenia can assist hea...
Objective: To determine the cost utility of treating schizophrenic patients with olanzapine compared...
AbstractObjectiveA 1-year semi-Markov model was constructed to simulate the cost-effectiveness of at...
Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” an...
Objective: To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophren...
Australia and Canada are currently the only Western nations with government guidelines for analyzing...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
Objectives: To compare the annual costs of treating schizophrenia with four atypical antipsychotics-...
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight dr...
Background: Schizophrenia is a major public health problem throughout the world and known to be a ma...
OBJECTIVE: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
BACKGROUND: Many patients with schizophrenia exhibit only a partial response to conventional antipsy...
© 2019, Serbia Medical Society. All rights reserved. Introduction/Objective Although effectiveness o...
Background: Information on cost-effectiveness of interventions to treat schizophrenia can assist hea...
Objective: To determine the cost utility of treating schizophrenic patients with olanzapine compared...
AbstractObjectiveA 1-year semi-Markov model was constructed to simulate the cost-effectiveness of at...
Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” an...
Objective: To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophren...
Australia and Canada are currently the only Western nations with government guidelines for analyzing...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...